Valuation: Denali Therapeutics Inc.

Market Cap 3.61B 3.15B 2.91B 2.68B 5.05B 347B 5.17B 34.77B 13.68B 170B 13.55B 13.25B 586B P/E 2026 *
-9.27x
P/E 2027 * -9.43x
Enterprise Value 2.93B 2.56B 2.37B 2.18B 4.11B 282B 4.2B 28.27B 11.12B 138B 11.02B 10.77B 476B EV / Sales 2026 *
73.8x
EV / Sales 2027 * 26.6x
Free-Float
90.08%
Yield 2026 *
-
Yield 2027 * -
1 day+4.03%
1 week-8.31%
Current month-8.46%
1 month+0.23%
3 months+14.46%
6 months+34.31%
Current year+42.61%
1 week 22.01
Extreme 22.01
26.6
1 month 22.01
Extreme 22.01
27.3
Current year 15.34
Extreme 15.34
27.3
1 year 12.58
Extreme 12.58
27.3
3 years 10.57
Extreme 10.57
33.33
5 years 10.57
Extreme 10.57
66.79
10 years 10.57
Extreme 10.57
93.94
Manager TitleAgeSince
Director of Finance/CFO 52 01/05/2022
Chief Executive Officer 50 01/08/2015
Chief Tech/Sci/R&D Officer 58 06/11/2025
Director TitleAgeSince
Director/Board Member 50 01/03/2015
Director/Board Member 73 01/04/2015
Director/Board Member 68 01/04/2015
Date Insider Type Main position Quantity % Market Cap.
6/3/26 A Free

Director

25,634 0.0162%
6/3/26 A Free

Director

25,634 0.0162%
6/3/26 A Free

Director

25,634 0.0162%
Change 5-day change 1-year change 3-year change Capi.($)
+4.03%-8.31%+62.04%-20.19% 3.61B
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-1.54%+53.22%+71.85% 53.69B
+0.70%-6.57%+3.69%+421.79% 23.29B
-0.02%+0.05%-17.56%-14.62% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%+0.03%+31.57%-30.42% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
-0.09%-1.73%+23.74%+189.32% 14B
Average -2.13%-2.78%+45.67%+164.57% 24.41B
Weighted average by Cap. -2.84%-2.41%+43.48%+142.32%

Financials

2026 *2027 *
Net sales 39.76M 34.75M 32.06M 29.55M 55.7M 3.83B 56.94M 383M 151M 1.88B 149M 146M 6.46B 111M 96.84M 89.36M 82.37M 155M 10.67B 159M 1.07B 420M 5.23B 416M 407M 17.99B
Net income -484M -423M -390M -360M -678M -46.62B -693M -4.67B -1.84B -22.83B -1.82B -1.78B -78.61B -466M -408M -376M -347M -653M -44.91B -668M -4.5B -1.77B -22B -1.75B -1.71B -75.72B
Net Debt -674M -589M -544M -501M -945M -64.95B -966M -6.5B -2.56B -31.81B -2.53B -2.48B -110B -663M -579M -535M -493M -929M -63.85B -950M -6.39B -2.51B -31.27B -2.49B -2.44B -108B
Logo Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.
Employees
507
Date Price Change Volume
17/07/26 $23.62 +3.89% 828,290
16/07/26 $22.73 -1.26% 2,441,932
15/07/26 $23.02 +1.63% 1,889,604
14/07/26 $22.65 -14.46% 5,778,165
13/07/26 $26.48 +3.12% 1,894,568
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
22.73USD
Average target price
34.25USD
Spread / Average Target
+50.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DNLI Stock